Oral mucosal immunotherapy (OMIT) via a toothpaste has been in the works since 2012 but it is still not FDA-approved as of 2019. The toothpaste base is called Allerdent (R). Most insurances do not pay for oral mucosal immunotherapy (OMIT) as of 2019 (see below). The cost is approximately $400 for 3 months. The recommended duration of treatment is 3 years. Several allergens can be mixed together.
Dr. William Reisacher, ENT, an associate professor of otolaryngology at Weill Cornell, is a co-founder and chief medical officer of Allovate, the company takes makes the Allerdent (R) oral mucosal immunotherapy (OMIT) toothpaste. In the video below he shows how to mix the allergens in the toothpaste base and load the dispenser:
In 2016, Dr. Reisacher published a review of alternative routes to allow IT: intralymphatic immunotherapy (ILIT), epicutaneous immunotherapy (EPIT), local nasal immunotherapy (LNIT), oral immunotherapy (OIT), and oral mucosal immunotherapy (OMIT) (http://vivo.med.cornell.edu/display/pubid84995912076).
From BC/BS website info:
The following allergy treatments are not covered because they are considered investigational including, but not limited to:
1) Provocative and neutralization therapy for food allergies, by sublingual, intradermal, and subcutaneous routes. Provocative and neutralization therapy involves administering neutralizing doses rather than standard doses of allergens either under the tongue or into the skin;
2) Sublingual immunotherapy (SLIT) except for the following FDA approved products: Oralair®, Grastek®, Ragwitek®, and Odactra.
3) Urine autoinjections (autogenous urine immunization) - (a substance from the urine is injected into the skin);
4) Repository emulsion therapy;
5) Low dose immunotherapy also known as the "Rinkel" technique;
6) Enzyme-Potentiated Desensitization;
7) Acupuncture for allergies;
8) Homeopathy for allergies;
10). Oral mucosal immunotherapy, including Allerdent® compounded toothpaste.
Subcutaneous immunotherapy performed in the home setting is considered investigational.
Allergy sufferers find relief in immunotherapy toothpaste - Fox News:
In 2017, Pediatric Allergy Solutions (“PAS”) and Allovate Therapeutics (“Allovate®”) announced that they have signed an exclusive agreement to combine PAS’s fingerstick allergy test and Allovate’s Allerdent®, a patented toothpaste-based system for the delivery of allergy immunotherapy to enable primary care physicians to offer personalized allergy care: https://vimeo.com/269966553